The US Food and Drug Administration (FDA) has approved Aquestive Therapeutics’ Exservan (riluzole oral film) for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a rare and fatal neurodegenerative disease that is characterised by progressive loss of motor neurons.

Exservan is a novel formulation of Sanofi’s Rilutek (riluzole), and historically this has been the standard of care for ALS patients as it secured the first-to-market position back in 1995.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The second drug to be approved for ALS was Mitsubishi Tanabe’s Radicava/Radicut (edaravone) in 2017.

Drugs are difficult to administer

However, both Rilutek and Radicava/Radicut have moderate efficacy at best, seeing that they can extend patient survival for up to six months. In addition, their respective route and frequency of administration are far from ideal for ALS patients. This means that, despite the rarity of the disease, there is a high level of unmet need in the market and significant opportunities for a pharmaceutical company to address.

Rilutek is an orally administered tablet that has to be given multiple times per day, which can be difficult for an advanced-stage ALS patient who has trouble swallowing.

See Also:

Radicava/Radicut is an intravenously administered drug and, again, this may be difficult for patients who are suffering from mobility issues. Some companies have identified this gap in the market and have been developing reformulations to minimize these compliance problems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

New drug Exservan dissolves on the tongue

A case in point is provided by Aquestive Therapeutics, because it has successfully developed an oral soluble film version of Rilutek, which dissolves on the tongue once administered and does not require water or the muscle action to swallow. Exservan’s improved formulation is expected to translate into a higher compliance rate and provide the drug with an important clinical advantage.

As such, according to GlobalData, the new drug is forecast to generate $16M in US sales in 2025. Aquestive has recently licensed the drug to Zambon Pharma for the development and commercialization of Exservan in Europe. Under the deal, Aquestive will be responsible for manufacturing the drug, while Zambon will focus on regulatory approval and marketing in Europe. Given that Zambon is based in Italy and already has experience in neurology, this deal is expected to boost the commercial potential of Exservan even further.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.